Three years treatment with HDM allergen immunotherapy, omalizumab, or combination therapy in allergic asthma: clinical outcomes and biomarkers.
Andrzej Bozek, Martyna Miodonska, Dominika Sadowska et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial evaluated the long-term effects of omalizumab, subcutaneous allergen immunotherapy (SCIT-HDM), and their combination in 79 patients with mild-to-moderate allergic asthma over 36 months. The combination therapy demonstrated the most significant benefits, with a clinical remission rate of 47% compared to 31% for omalizumab alone and 29% for SCIT-HDM.
Key findings
- Combination therapy resulted in lower exacerbation rates compared to other groups.
- 47% of patients in the combination therapy group achieved clinical remission.
- Significant reductions in inhaled corticosteroid use were observed in groups A and B.
- Improvements in Asthma Control Test scores were noted across all treatment groups.
Why it matters
Understanding the comparative effectiveness of these therapies can guide clinicians in optimizing treatment strategies for patients with allergic asthma, potentially improving long-term outcomes and quality of life.
What to keep in mind
The study's small sample size may limit the generalizability of the findings.